A new JAMA clinical investigation examined whether low-dose rivaroxaban reduces cardiovascular events in patients with advanced chronic kidney disease and elevated cardiovascular risk. The study addresses a persistent evidence gap because anticoagulation decisions in advanced CKD often carry competing concerns about bleeding risk and uncertain event reduction. The report’s framing emphasizes efficacy and safety in a high-risk, comorbidity-heavy population where both thromboembolic events and hemorrhagic complications are clinically consequential. For biotech and clinical developers, the results matter for how anticoagulant strategies may evolve in CKD, potentially affecting trial design for future cardiovascular-protective agents. Any practice shift will likely depend on net clinical benefit across risk strata, including kidney function levels and baseline bleeding risk.